Drug
Erdosteine
Erdosteine is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
20%
Ph phase_2
1
20%
Ph not_applicable
1
20%
Ph phase_3
1
20%
Ph phase_4
1
20%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(1)
Terminated(1)
Other(1)
Detailed Status
unknown1
Completed1
Recruiting1
Withdrawn1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
N/A1 (20.0%)
Trials by Status
unknown120%
completed120%
recruiting120%
withdrawn120%
not_yet_recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
not_yet_recruitingnot_applicable
Immuno-inflammatory Response of Erdosteine in COPD
NCT07329946
recruitingphase_1
Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
NCT07242222
withdrawnphase_4
Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
NCT01176318
unknownphase_3
The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)
NCT01032304
completedphase_2
Phase 2 Study - Erdosteine in Patients With CB/COPD
NCT00338507
Clinical Trials (5)
Showing 5 of 5 trials
NCT07329946Not Applicable
Immuno-inflammatory Response of Erdosteine in COPD
NCT07242222Phase 1
Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
NCT01176318Phase 4
Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
NCT01032304Phase 3
The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)
NCT00338507Phase 2
Phase 2 Study - Erdosteine in Patients With CB/COPD
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5